Brief: Oncolytics Biotech Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
10/12/2021 12:04
Dec 10 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PRESENTS POSITIVE INTERIM SAFETY
UPDATE FROM
PHASE 2 TRIPLE-NEGATIVE BREAST CANCER TRIAL AT THE 2021 SAN
ANTONIO BREAST CANCER SYMPOSIUM
* ONCOLYTICS BIOTECH INC - NO SAFETY CONCERNS HAVE BEEN
NOTED IN
ANY TRIAL PARTICIPANTS
Source text for Eikon: ID:nCNWPlzzHa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer